CD274 and neoplasm: Overcoming this obstacle and achieving the personalized use of these agents requires a stepwise approach: first, taking into account the previously mentioned shortcomings of PD-L1 as a potential biomarker, it is important to retrospectively identify, in the large amount of collected tumor material from prospective studies, novel predictive biomarkers.